P-584 Single agent gemcitabine (GEM) in performance status (PS) 2–3patients (pts) with advanced non-small cell lung cancer (NSCLC): Effect on disease-related symptoms in a multicenter phase II trial

Autor:	Paolo Pronzato, Alessandra Tognoni, C. Carob, T. Coialbu, M.C. Pennucci, F. Brema, F. Grossi, Manlio Mencoboni, A. Ardizzoni, Marcello Tiseo
Rok vydání:	2005
Předmět:	Pulmonary and Respiratory Medicine Oncology Cancer Research medicine.medical_specialty Performance status business.industry non-small cell lung cancer (NSCLC) Disease medicine.disease Gemcitabine Internal medicine medicine Single agent business medicine.drug
Zdroj:	Lung Cancer. 49:S272
ISSN:	0169-5002
DOI:	10.1016/s0169-5002(05)81077-3
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::a7a843adce2d2b35fb49229b919f4e89 https://doi.org/10.1016/s0169-5002(05)81077-3 Zobrazit plný text záznamu Full Text from ScienceDirect